George J. Morrow, Director at NEUROCRINE BIOSCIENCES INC (NBIX), sold 15,000 shares at $149.00 ($2.3M) on 2026-10-30, disclosed to the SEC on 2026-11-03.
Scheduled sale ($2.3M) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $149.00 | 300 | $45K | 1.9% |
| 2 | $144.98 | 1,900 | $275K | 11.8% |
| 3 | $145.86 | 4,300 | $627K | 26.8% |
| 4 | $146.76 | 1,300 | $191K | 8.2% |
| 5 | $158.18 | 100 | $16K | 0.7% |
| 6 | $162.05 | 100 |
| $16K |
| 0.7% |
| 7 | $163.71 | 600 | $98K | 4.2% |
| 8 | $164.74 | 1,226 | $202K | 8.6% |
| 9 | $165.71 | 908 | $150K | 6.4% |
| 10 | $166.77 | 1,466 | $244K | 10.5% |
| 11 | $167.72 | 1,500 | $252K | 10.8% |
| 12 | $168.53 | 1,300 | $219K | 9.4% |
| Total | $155.73 avg | 15,000 | $2.3M | 100% |
| Filing → |
| ALGN | SELL | 2021-08-03 | $6.0M | — | Filing → |
| ALGN | SELL | 2021-02-08 | $18.7M | — | Filing → |
| ALGN | SELL | 2020-11-04 | $2.4M | — | Filing → |